KEI Comments on NIH Prospective Exclusive License to Gilead for HIV Treatment/Cure

On October 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the ““Prospective Grant of an Exclusive Patent License: Development of a Bispecific T Cell Engager for the Treatment and Cure of HIV-1”… Continue Reading

KEI Comments Regarding NIH Exclusive License to RNAceuticals for Anti-HIV Antibodies

On July 27, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV… Continue Reading

U.S. DoS Cable: Brazil’s National Health Council Recommends Compulsory Licensing – August 12, 2005

  R 122031Z AUG 05 – August 12, 2005FM AMEMBASSY BRASILIATO SECSTATE WASHDC 2501SUBJECT: Brazil’s National Health Council Recommends Compulsory Licensing of Antiretrovirals 1. SENSITIVE BUT UNCLASSIFIED 2. (SBU) Summary.  Adding to the tension surrounding negotiations between the ministry of… Continue Reading